Extended cycle multiphasic oral contraceptive method
View Patent ↗A multiphasic method of contraception provides for sequentially administering to a female of child bearing age: (a) a Phase I composition containing a progestogen and an estrogen for about 4 to about 7 days; (b) a Phase II composition containing a progestogen and an estrogen for about 8 to about 16 days; (c) a Phase III composition containing a progestogen and an estrogen for about 4 to about 7 days; and (d) optionally, a Phase IV composition which is a placebo or a non-steroidal component, wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions. Preferably the sequential administration is repeated the day following the completion of the administration of the Phase III compositions providing an extended cycle multiphasic oral contraceptive method.
1. A multiphasic method of contraception comprising the steps of sequentially administering to a female of child bearing age:
(a) a Phase I composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 30 mcg of ethinyl estradiol for about 4 to about 7 days;
(b) a Phase II composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 10 to about 40 mcg of ethinyl estradiol for about 8 to about 16 days;
(c) a Phase III composition containing a progestogen in an amount equivalent to about 0.3 to about 1.5 mg of norethindrone acetate and an estrogen in an amount equivalent to about 5 to about 30 mcg of ethinyl estradiol for about 4 to about 7 days
wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions, wherein the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is equal to the ethinyl estradiol equivalent amount of estrogen in the Phase I composition, and wherein the sequential administration of the Phase I, II, and III compositions is repeated the day following the completion of the administration of composition III to provide an extended contraceptive cycle, there is no decrease in the norethindrone acetate equivalent amount of progestogen from the administration of the Phase III composition to the administration of the Phase I composition in the extended contraceptive cycle and the extended contraceptive cycle is from about 42 to about 140 days.
2. The method according to claim 1 , wherein a Phase IV composition which is a placebo or a non-steroidal component is administered upon completion of the extended contraceptive cycle for about 2 to about 9 days.
3. The method of claim 2 , wherein said non-steroidal composition comprises ferrous fumarate.
4. The method according to claim 1 , wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least about 10 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions.
5. The method according to claim 1 , wherein the norethindrone acetate equivalent amount of progestogen in the Phase I, II, and III compositions is about 1 mg of norethindrone acetate.
6. The method according to claim 5 , wherein the ethinyl estradiol equivalent amount of estrogen in the Phase I composition is about 20 mcg of ethinyl estradiol, the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is about 25 mcg of ethinyl estradiol, and the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is about 20 mcg of ethinyl estradiol.
7. The method according to claim 5 , wherein the ethinyl estradiol equivalent amount of estrogen in the Phase I composition is about 25 mcg of ethinyl estradiol, the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is about 30 mcg of ethinyl estradiol, and the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is about 25 mcg of ethinyl estradiol.
8. The method according to any one of claims 6 and 7 , wherein the estrogen and progestogen in the Phase I, II and III compositions are, respectively, ethinyl estradiol and norethindrone acetate.
9. The method according to claim 8 , wherein the Phase I composition is administered for about 5 days for each sequential administration, the Phase II composition is administered for about 11 to about 14 days for each sequential administration, and the Phase III composition is administered for about 5 days for each sequential administration.
10. The method according to claim 9 , wherein a Phase IV composition which is a placebo or a non-steroidal component is administered for about 2 to about 9 days upon completion of extended contraceptive cycle.
11. The method according to claim 2 wherein the norethindrone acetate equivalent amount of progestogen in the Phase I composition is about 1.0 mg of norethindrone acetate and is administered for about 5 days, the norethindrone acetate equivalent amount of progestogen in the Phase II composition is about 1.0 mg of norethindrone acetate and is administered for about 11 days, the norethindrone acetate equivalent amount of progestogen in the Phase III composition is about 1.0 mg of norethindrone acetate and is administered for about 5 days, and the Phase IV composition contains about 75 mg of ferrous fumarate and is administered for about 7 days.
12. The method according to claim 2 , wherein the norethindrone acetate equivalent amount of progestogen in the Phase I composition is about 1.0 mg of norethindrone acetate and is administered for about 5 days, the norethindrone acetate equivalent amount of progestogen in the Phase II composition is about 1.0 mg of norethindrone acetate and is administered for about 14 days, the norethindrone acetate equivalent amount of progestogen in the Phase III composition is about 1.0 mg of norethindrone acetate and is administered for about 5 days, and the Phase IV composition contains about 75 mg of ferrous fumarate and is administered for about 4 days.
13. The method according to any one of claims 11 and 12 , wherein the ethinyl estradiol equivalent amount of estrogen in the Phase I composition is about 25 mcg of ethinyl estradiol, the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is about 30 mcg of ethinyl estradiol, and the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is about 25 mcg of ethinyl estradiol.
14. The method according to claim 13 , wherein the estrogen and progestogen in the Phase I, II and III compositions are, respectively, ethinyl estradiol and norethindrone acetate.
15. The method according to any one of claims 11 and 12 , wherein the ethinyl estradiol equivalent amount of estrogen in the Phase I composition is about 20 mcg of ethinyl estradiol, the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is about 25 mcg of ethinyl estradiol, and the ethinyl estradiol equivalent amount of estrogen in the Phase III composition is about 20 mcg of ethinyl estradiol.
16. The method according to claim 15 , wherein the estrogen and progestogen in the Phase I, II and III compositions are, respectively, ethinyl estradiol and norethindrone acetate.
17. The method according to claim 1 , wherein the progestogen is selected from the group consisting of norethindrone acetate, drospirenone, trimegestone, norethindrone, levonorgestrel, desogestrel, 3-ketodesogestrel, gestodene, demegestone, dydrogesterone, medrogestone, medroxy progesterone, esters and mixtures thereof.
18. The method according to claim 1 , wherein the estrogen is selected from the group consisting of ethinyl estradiol, 17-β-estradiol, conjugated estrogens, mestranol, estrone, and esters prodrugs and salts thereof.
19. The method according to anyone of claims 2 , 3 , or 4 , wherein each of compositions I, II and III independently contain a progestogen in an amount equivalent to about 0.5 to about 1.5 mg norethinedrone acetate.